A retrospective study of first‐line therapy and subsequent pyrotinib treatment in advanced lung adenocarcinoma with HER2 mutations

Documenti analoghi

• Prognostic impact of the timing of immunotherapy in first‐line immunochemotherapy for patients with advanced lung adenocarcinoma: A propensity score‐matched analysis
  di: Yanxin Sun, et al.
  Pubblicazione: (2025)
• Major advancements in first‐line treatments for advanced urothelial cancer
  di: Mary Beth Nierengarten
  Pubblicazione: (2024)
• Efficacy of ramucirumab combination chemotherapy as second‐line treatment in patients with advanced adenocarcinoma of the stomach or gastroesophageal junction after exposure to checkpoint inhibitors and chemotherapy as first‐line therapy
  di: Michael Masetti, et al.
  Pubblicazione: (2024)
• HER2 mutation as an emerging target in advanced breast cancer
  di: Giulia Bon, et al.
  Pubblicazione: (2024)
• Clinical relevance of somatic mutations in Chinese lung adenocarcinoma and their prognostic implications for survival
  di: Tongxin Li, et al.
  Pubblicazione: (2024)